DCM
BIOTW

DG Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

DG Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-224,999
Closed -$148K – 169
2021
Q3 		$148K Hold
224,999
– – 0.03% 123
2021
Q2 		$193K Buy
+224,999
New +$156K 0.04% 115

Other funds holding BIOTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

DG Capital Management's BIOTW Position: Q4 2021 in Review

DG Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q4 2021, closing a stake of 224,999 shares — an estimated $148K sold.

DG Capital Management first reported a position in BIOTW in Q2 2021 and held it in 2 quarters. The position peaked at $193K in Q2 2021. 56 funds tracked by Wall St. Rank hold BIOTW as of Q4 2021.

  • DG Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q4 2021 after selling out during the quarter.
  • DG Capital Management sold 224,999 Biotech Acquisition Company Warrant shares in Q4 2021, an estimated $148K.
  • DG Capital Management first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 2 quarters.
  • DG Capital Management's Biotech Acquisition Company Warrant position peaked at $193K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q4 2021.

Based on DG Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.